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Background and Aims: Primary sclerosing cholangitis (PSC) is associated 
with increased risk of cholangiocarcinoma (CCA). Early and accurate CCA 
detection represents an unmet clinical need as the majority of patients with 
PSC are diagnosed at an advanced stage of malignancy. In the present study, 
we aimed at establishing robust DNA methylation biomarkers in bile for early 
and accurate diagnosis of CCA in PSC.
Approach and Results: Droplet digital PCR (ddPCR) was used to ana-
lyze 344 bile samples from 273 patients with sporadic and PSC- associated 
CCA, PSC, and other nonmalignant liver diseases for promoter methylation 
of cysteine dioxygenase type 1, cannabinoid receptor interacting protein 1, 
septin 9, and vimentin. Receiver operating characteristic (ROC) curve analy-
ses revealed high AUCs for all four markers (0.77– 0.87) for CCA detection 
among patients with PSC. Including only samples from patients with PSC 
diagnosed with CCA ≤ 12 months following bile collection increased the ac-
curacy for cancer detection, with a combined sensitivity of 100% (28/28) and 
a specificity of 90% (20/203). The specificity increased to 93% when only 
including patients with PSC with longtime follow- up (> 36 months) as controls, 
and remained high (83%) when only including patients with PSC and dys-
plasia as controls (n = 23). Importantly, the bile samples from the CCA- PSC 
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INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic 
cholestatic liver disease, characterized by progressive 
inflammation and fibrosis of the biliary tree.[1– 3] In the 
absence of any effective medical treatment, the ma-
jority of patients with PSC develop end- stage liver dis-
ease, with liver transplantation representing the only 
curative option.[1] Although 5- year survival after liver 
transplantation is good (exceeds 80%), development 
of cholangiocarcinoma (CCA) prior to transplantation 
represents a feared complication of PSC, with a major 
negative impact on life expectancy.[3,4]
Patients with PSC have a 160- fold to 600- fold in-
creased lifetime risk of developing CCA compared to 
the general population, amounting to a 20% reported 
lifetime incidence of CCA.[4– 7] CCA in PSC is com-
monly diagnosed at a young age (40– 50 years), in con-
trast to sporadic CCA that often develops at a more 
advanced age (70– 80 years).[5] Detecting CCA in PSC 
is challenging, partly due to nonspecific presenting fea-
tures and overlapping findings in malignant and benign 
disease progression in PSC. Even with combined use 
of multiple detection modalities, including tumor serum 
marker carbohydrate antigen 19- 9 (CA 19- 9), imag-
ing, biliary brushing for cytological and fluorescence 
in situ hybridization (FISH) evaluation, and intraductal 
biopsies, the diagnostic accuracy for CCA in PSC is 
low.[8– 10] Consequently, CCA is commonly detected 
at an advanced stage. Owing to late diagnosis, CCA 
carries a dismal prognosis among patients with PSC. 
The median survival is < 12 months in patients with 
unresectable disease, and CCA currently represents 
the most frequent cause of PSC- associated deaths.[5] 
If CCA is detected at an early stage, curative surgi-
cal resection or liver transplantation is possible, with 
reported 5- year survival rates up to 35% and 74%, 
respectively.[11,12] As earlier tumor detection may signifi-
cantly improve survival among patients with PSC and 
CCA, establishment of accurate detection methods for 
early- stage CCA, which can be implemented in surveil-
lance algorithms, represents a clear unmet need.
Aberrant DNA methylation alterations are valuable as 
cancer biomarkers, including early detection markers. 
They are highly prevalent in most cancer types, may be 
found in precancerous lesions or early- stage cancers, 
and may further be detected in various body fluids that 
can be obtained by noninvasive or minimally invasive 
procedures.[13] In patients with CCA, aberrant DNA 
methylation has been observed in both blood and bile, 
emphasizing the potential of such markers for early 
detection of CCA.[13,14] We have previously identified a 
DNA methylation biomarker panel suitable for detecting 
CCA, with high sensitivity (85%) and specificity (98%), 
using biliary brushes.[15] In the current study we aimed 
at validating these markers in small volumes of bile for 
early and accurate detection of CCA in patients with 
PSC, using droplet digital PCR (ddPCR).
MATERIALS AND METHODS
Patient samples and clinical data
A total of 344 bile samples from 273 patients diag-
nosed with CCA (with or without underlying PSC), PSC 
with biliary dysplasia, nonmalignant (NM) PSC, and 
other benign liver diseases were included in the study. 
Patients were recruited at Oslo University Hospital, 
Rikshospitalet (Oslo, Norway; n = 219), Karolinska 
University Hospital (Stockholm, Sweden; n = 12), and 
Helsinki University Hospital (Helsinki, Finland; n = 42) 
between 2008 and 2019. Diagnosis of PSC was based 
on typical findings on magnetic resonance cholangio-
graphy and/or endoscopic retrograde cholangiopancre-
atography (ERCP) according to established criteria.[3,16] 
CCA diagnosis was established by histopathologi-
cal analysis of tissue samples or through combined 
clinical, biochemical, radiological, and cytological as-
sessments.[3,17] Diagnosis of low- grade or high- grade 
biliary dysplasia was based on evaluation of biliary 
brush specimens using standard cytological criteria 
or, in patients undergoing liver transplantation, by his-
topathological examination of the explanted liver.[18,19] 
In addition, all obtained brush cytologies were classi-
fied into the following categories: 0, acellular; 1, nor-
mal; 2, atypia; 3, suspicious of carcinoma; 4, diagnostic 
of carcinoma (Table S1). Patients with CCA receiving 
Funding information
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(project 40093, to G.E.L.; 2017016, to 
M.M.G.)
≤ 12 patients, all positive for the biomarkers, included both early- stage and 
late- stage CCA, different tumor growth patterns, anatomical locations, and 
carbohydrate antigen 19- 9 levels.
Conclusions: Using highly sensitive ddPCR to analyze robust epigenetic bi-
omarkers, CCA in PSC was accurately detected in bile, irrespective of clinical 
and molecular features, up to 12 months before CCA diagnosis. The findings 
suggest a potential for these biomarkers to complement current detection and 
screening methods for CCA in patients with PSC.
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chemotherapy at the time of bile sampling were not in-
cluded in the study.
Samples were split based on main disease cate-
gory, including (1) patients with underlying PSC and 
(2) patients with non- PSC- related diseases (Figure 1). 
The PSC group was divided into two main groups: (1) 
CCA- PSC (n = 38 [42 samples], including patients with 
CCA and concomitant PSC) and (2) PSC all (n = 205 
[272 samples], including benign PSC without CCA). The 
CCA- PSC group was further divided into subgroups 
based on time from bile sampling to a confirmed CCA 
diagnosis using standard diagnostic criteria, including 
(1) CCA- PSC ≤ 12 (n = 28 [31 samples], ≤ 12 months 
from bile sampling to a confirmed CCA diagnosis) and 
(2) CCA- PSC > 12 (n = 10 [11 samples], > 12 months 
from bile sampling to CCA diagnosis). We chose a 
threshold of 12 months from bile sampling to an estab-
lished CCA diagnosis to increase the likelihood of CCA 
actually being present (CCA- PSC ≤ 12) and simulta-
neously to see if the markers could detect CCA earlier 
(up to 12 months) than currently used detection meth-
ods. The benign PSC group was further divided into 
(1) PSC- dysplasia (n = 23 [24 samples], patients with 
PSC and evidence of biliary dysplasia based on as-
sessment of biliary brush cytology specimens or histo-
logical assessment of explant liver ±2 months from bile 
collection but with no evidence of CCA development), 
(2) PSC- control > 36 (n = 170 [226 samples], patients 
with PSC with no evidence of CCA or biliary dyspla-
sia based on histological assessment of explanted liver 
at or after bile collection or > 36 months of follow- up 
[median 105 months] without established CCA or biliary 
dysplasia for nontransplanted patients), and (3) PSC- 
control < 36 (n = 12 [22 samples], patients with PSC 
with no evidence of CCA or biliary dysplasia after bile 
collection but only including nontransplanted patients 
with < 36 months of follow- up [median 26 months]). 
We chose a threshold of 36 months of follow- up from 
bile sampling to divide the benign PSC group in two, 
to minimize the probability of presence of CCA in the 
strictest control group (PSC- control > 36). We further 
included PSC- dysplasia as a separate group to eval-
uate the methylation pattern in this potentially prema-
lignant group. The non- PSC group was divided into (1) 
F I G U R E  1  Flowchart of bile samples included in the study. Number of patients, followed by number of samples in parentheses. 
Samples are split based on main disease category, including (1) patients with underlying PSC (left panel) and (2) patients with non- 
PSC- related diseases (right panel). PSC samples (left panel) are divided into the following groups: (1) CCA- PSC (n = 38, 42 samples), 
including CCA- PSC ≤ 12 (n = 28, 31 samples; ≤ 12 months from bile sampling to CCA diagnosis) and CCA- PSC > 12 (n = 10, 11 samples; 
> 12 months from bile sampling to CCA diagnosis), and (2) all PSC samples (without CCA, n = 205, 272 samples), including PSC- dysplasia 
(n = 23, 24 samples; patients with PSC with evidence of biliary dysplasia based on assessment of biliary brush cytology specimens or 
histological assessment of explant liver ±2 months from bile collection), PSC- control > 36 (n = 170, 226 samples; patients with PSC with no 
evidence of CCA or biliary dysplasia based on histological assessment of explanted liver at or after bile collection or > 36 months of follow- 
up without established CCA or biliary dysplasia for nontransplanted patients), and PSC- control < 36 (n = 12, 22 samples; patients with PSC 
with no evidence of CCA or biliary dysplasia after bile collection but only including nontransplanted patients with < 36 months of follow- up). 
Non- PSC samples (right panel) are divided into (1) CCA (n = 6, 6 samples, of which five were collected at the same time as a confirmed 
CCA diagnosis and one was collected 3 months prior to diagnosis) and (2) NM liver disease (n = 24, 24 samples; hereditary, idiopathic 
nonalcoholic fatty liver, biliary stone, and autoimmune liver disease other than PSC)
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CCA (n = 6 [6 samples]) and (2) other NM liver diseases 
(n = 24 [24 samples], including hereditary, idiopathic 
nonalcoholic fatty liver, biliary stone, and autoimmune 
liver disease other than PSC). The samples in the non- 
PSC group were included to explore the methylation 
levels of the markers in non- PSC- related CCA and 
other NM liver diseases.
Bile was collected during ERCP, if possible before 
injecting contrast medium; at liver transplantation; or in 
one case at liver resection. All samples were stored at 
−80℃ or −20℃ (Karolinska University Hospital) prior to 
DNA extraction.
For summarized clinical and histopathological infor-
mation of the included samples, see Tables 1 and 2; 
and for detailed information about each bile sample, 
see Table S1.
DNA extraction
For DNA extraction, using aliquots of 100– 200 µl of 
bile per sample, three methods were tested: High 
Pure Viral (Roche Diagnostics, Basel, Switzerland), 
PrepFiler (Thermo Fisher Scientific, MA), and a stand-
ard phenol chloroform procedure. The phenol chloro-
form procedure was performed as described,[15] while 
the manufacturers’ protocols were followed for the Pure 
Viral and the PrepFiler kits. Resulting DNA yields were 
measured using NanoDrop ND- 1000. The High Pure 
Viral kit provided the highest amount of DNA (mean 
output of four samples, 532 ng), followed by phenol 
chloroform (mean output of three samples, 72 ng) 
and PrepFiler (mean output of four samples, 22.5 ng) 
(Table S2).
To compare the amount of amplifiable DNA from 
the three extraction methods, samples were bisulfite- 
treated (described in the following section), and 32 ng 
of bisulfite- treated DNA (from each sample) was ampli-
fied by quantitative methylation specific PCR (qMSP) 
as described,[20] using the ALU primer and probe set. 
Following bisulfite treatment and qMSP amplification, 
phenol chloroform outperformed the two kits, with lower 
ALU cycle threshold values, indicating more amplifiable 
DNA (Table S2). For the 350 bile samples reported in 
the following, DNA was extracted from 100 to 200 µl 
bile using the phenol chloroform procedure.
Bisulfite treatment
Five- hundred nanograms of DNA was bisulfite- 
converted using the EpiTect bisulfite kit (Qiagen, Hilden, 
TA B L E  1  Clinical characteristics separated by groups
CCA- PSC (n = 38) PSC (n = 205)
Gender (male) 76% 76%
Median age CCA diagnosis, years (range) 53.9 (46.0) NA
Median age benign liver diagnosis, years (range) 49.4 (51.1) 31.0 (59.1)
IBD, number (%)
Crohn's 5 (13) 29 (14)
UC 22 (58) 115 (56)
Indet. colitis 0 (0) 3 (1)
No 9 (24) 50 (24)
NA 2 (5) 8 (4)
Cirrhosis, number (%)
Yes 5 (13) 39 (19)
No 20 (53) 152 (74)
NA 13 (34) 14 (7)
Acute cholangitis, number (%)
Yes 2 (5) 1 (0)
No 36 (95) 204 (100)
NA 0 (0) 0 (0)
Median CA19- 9 level, U/ml (range) 47 (8,638) 19 (384)
Missing 3 10
Dead 74% 3%
Abbreviations: IBD, inflammatory bowel disease; Indet., indeterminate; NA, not available; UC, ulcerative colitis.
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Germany) according to the manufacturer's protocol. 
Desulfonation of the samples was performed using a 
QIAcube (Qiagen) with elution in 40 µl buffer.
DNA methylation analyses
Primer and probe sequences for the target genes 
cysteine dioxygenase type 1 (CDO1), cannabinoid re-
ceptor interacting protein 1 (CNRIP1), septin 9 (SEPT9), 
and vimentin (VIM) and the 4Plex control comprising 
ephrin type A receptor 3, kelch repeat and BTB do-
main containing 4, pleckstrin homology and FYVE do-
main containing 1, and synaptotagmin 10 have been 
published.[15,21]
The QX200 Droplet Digital PCR System (BioRad) 
was used for DNA methylation analyses. The ddPCR 
consisted of 1 × ddPCR Supermix for Probes (BioRad), 
818 nM of each primer, 182 nM of each probe, and 30 ng 
bisulfite- converted DNA template, in a final volume of 
22 µl. Droplet generation was performed in the QX200 
Droplet Generator, using 20 µl of the ddPCR mixture 
and 70 µl droplet generation oil (BioRad). Samples were 
transferred to a 96- well PCR plate (BioRad) and sealed 
in the PX1 PCR Plate Sealer (BioRad). The PCR was 
performed in a T100 Thermal Cycler (BioRad), using 
the manufacturer's recommended cycling conditions. 
Using a ramp rate of 2℃/s, amplification was performed 
at 95℃ for 10 min, before 40 cycles of 30 s at 94℃ and 
1 min at 60℃, followed by enzyme deactivation at 98℃ 
for 10 min. The QX200 Droplet Reader (BioRad) was 
applied for detection of fluorescence signals.
Data analysis was performed using QuantaSoft, ver-
sion 1.7.4.0917 (BioRad). An in- house developed algo-
rithm, PoDCall (https://bioco nduct or.org/packa ges/relea 
se/bioc/html/PoDCa ll.html), was applied for positive 
droplet calling as described.[21] Normalized DNA methyl-
ation levels were calculated by dividing the concentration 
(copies per microliter) of the target gene by the concen-
tration (copies per microliter) of the 4Plex and multiplying 
by 400. For each target gene, samples with low DNA 
amount (4Plex concentration < 10 copies/µl) were ex-
cluded. Six samples had a 4Plex concentration < 10 for 
all the target genes (and were excluded altogether), and 
six samples had a 4Plex concentration < 10 for one to 
three genes and were excluded for the specific gene(s).
TA B L E  2  Histopathological data for patients with CCA- PSC







AJCC 0 1 (3)
AJCC 1 1 (3)
AJCC 2 6 (16)
AJCC 3 15 (39)





























Low (G3) 4 (11)
Medium (G2) 11 (29)
High (G1) 1 (3)
NA 22 (58)
Growth pattern
Mass- forming 10 (26)
Periductal- infiltrating 6 (16)
(Continues)
n = 38 Number (%)
Intraductal- growing 1 (3)
NA 21 (55)
Note: The stage is from time of diagnosis.
Abbreviations: AJCC 0– 4, American Joint Committee on Cancer 
classification stages 0– 4; G, grade of differentiation; M, distant metastases; 
N, lymph node metastases; NA, not available; T, tumor stage evaluation; 
xCCA, unclassifiable CCA subtype.
TA B L E  2  (Continued)
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Statistical analysis
A Mann- Whitney U test was used to test for differences 
in DNA methylation levels between the defined sample 
groups, and Fisher's exact test was used to examine 
the relation between methylation status (methylated 
or unmethylated for one or more of four markers) 
and sample group, as well as clinical and pathologi-
cal data. Receiver operating characteristic (ROC) 
curve analysis was performed to evaluate the diag-
nostic biomarker potential of the individual markers. 
In addition, combined ROC curves were generated by 
summarizing the normalized methylation values for 
the four markers. The AUC, sensitivities, specificities, 
and 95% CIs were calculated. The cutoff providing the 
highest possible specificity (> 90%) without compro-
mising the sensitivity was chosen for dichotomizing 
the samples. In cases where multiple samples from 
the same patient were analyzed, only one sample 
was selected for biomarker analysis. Samples in the 
group PSC- dysplasia were selected over PSC- control 
> 36, which were selected over PSC- control < 36. For 
the remaining samples, random selection was per-
formed, to select only one sample from each patient. 
Samples lacking methylation values (CDO1, n = 1 
[0.3%]; CNRIP1, n = 1 [0.3%]; SEPT9, n = 1 [0.3%]; 
VIM, n = 4 [1.2%]) were excluded. In the analyses of 
the biomarker panel, only samples with information 
for all four markers were included. Four samples were 
excluded because of missing values. Overall survival 
was calculated from time of bile sampling until death 
from any cause, and cases were censored at last 
follow- up. The effect of the four methylation markers 
was independently evaluated in a univariate approach, 
using the log rank method. The Kaplan- Meier method 
was used to estimate the survival curve. The analyses 
were performed using GraphPad Prism 8.1.2 and IMB 
SPSS Statistics 25.
Written informed consent was obtained from all 
study subjects. For long- archived samples, where this 
was not possible, an exception from informed consent 
was obtained by the local ethics committee to allow 
use of the samples. Study protocols were approved by 
the ethics committees of all the recruiting centers, as 
well as the Regional Committee for Medical and Health 
Research Ethics South Eastern Norway (6.2008.1723), 
the Swedish Ethical Review Authority (2013/2084- 
31/2 with amendment 2016/1023, 2018/1786- 32), and 
Helsinki University Hospital (278/13/03/01/2009).
RESULTS
A total of 344 samples from 273 patients passed the 
inclusion criteria after ddPCR, including 44 patients 
(48 samples) with CCA, of whom 38 (42 samples) had 
concomitant PSC, and 229 (296 samples) patients with 
NM liver diseases, of whom 205 (272 samples) had 
PSC. All of these samples were subjected to down-
stream analyses, with the most detailed analyses per-
formed among patients with CCA complicated with 
PSC and PSC controls (Figure 1; Table S1).
CCA- PSC versus PSC- controls
High accuracy for CCA detection in patients 
with underlying PSC up to 12 months prior 
to CCA diagnosis established by standard 
diagnostic modalities
To investigate the potential of the four DNA methylation 
markers to detect CCA in patients with underlying PSC, 
we included all CCA samples derived from patients with 
concomitant PSC (n = 38), and as controls we included all 
patients with PSC (n = 205), irrespective of the presence 
of dysplasia and length of follow- up. First, we compared 
the normalized methylation levels of all four markers in 
the two groups, showing that samples from patients with 
CCA- PSC displayed significantly higher methylation lev-
els than samples from patients with PSC for all four mark-
ers (Mann- Whitney U, p < 0.0001; Figure S1). Second, 
we did a ROC curve analysis to see how well the markers 
could differentiate between CCA- PSC and PSC. Plotting 
the normalized DNA methylation values from the CCA- 
PSCs against the normalized DNA methylation values 
from PSCs demonstrated that the individual biomarkers 
had high accuracy in distinguishing the two groups, with 
AUCs, sensitivities, and specificities ranging 0.77– 0.87, 
54%– 76%, and 93%– 98%, respectively (Figure 2A). 
Thirty of the 38 CCA samples had at least one methyl-
ated marker (79% sensitivity for the biomarker panel), 
while only 20 of the 203 samples (with valid DNA bio-
marker results) from patients with PSC were positive for 
the methylation panel (90% specificity). Combining the 
markers resulted in an AUC of 0.88 (Figure S2A).
Further, to see if time from bile sampling to a CCA 
diagnosis could affect the sensitivity of the DNA meth-
ylation markers, we included only CCA samples from 
patients diagnosed with CCA- PSC ≤ 12 months from 
F I G U R E  2  ROC curves, calculated AUCs, and sensitivity and specificity values for the four individual DNA methylation biomarkers in 
bile. (A) Samples from patients with CCA- PSC (n = 38) versus all PSC (n = 205), (B) samples from patients with PSC diagnosed with CCA 
≤ 12 months after bile sampling (CCA- PSC ≤ 12, n = 28) versus PSC all (n = 205), (C) CCA- PSC ≤ 12 (n = 28) versus PSC- control > 36 
(n = 170, including samples from patients with PSC showing no evidence of biliary dysplasia or CCA in explanted liver or with > 36 months 
of follow- up), and (D) CCA- PSC ≤ 12 (n = 28) versus PSC- dysplasia (n = 23, including patients with PSC with evidence of biliary dysplasia 
based on assessment of biliary brush cytology specimens or histological assessment of explant liver ±2 months from bile collection) 
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bile sampling (n = 28). As controls, we included (1) all 
PSC samples (n = 205), (2) samples from the PSC- 
control > 36 group (n = 170; no evidence of CCA or 
biliary dysplasia based on histological assessment 
of explanted liver or > 36 months of follow- up in non-
transplanted patients), and (3) PSC- dysplasia (n = 23; 
patients with PSC with evidence of biliary dysplasia 
based on assessment of biliary brush cytology spec-
imens or histological assessment of explanted liver 
±2 months from bile collection but with no evidence 
of CCA development). ROC curve analysis, plotting 
the normalized DNA methylation values for CCA- 
PSC ≤ 12 against the normalized values for all PSC 
samples showed that the ability to separate the two 
groups was high, with AUCs of 0.98 (CNRIP1), 0.94 
(CDO1), 0.88 (SEPT9), and 0.84 (VIM). The sensitivi-
ties and specificities of the individual markers ranged 
67%– 96% and 93%– 98%, respectively (Figure 2B). 
Interestingly, the sensitivity for the biomarker panel 
(defined by one or more of four methylation positive 
markers) was 100% with a specificity of 90%. Including 
only the PSC- control > 36 as controls increased the 
specificity for the biomarker panel to 93% (Figure 2C). 
Finally, we included only the PSC- dysplasia samples 
as controls. The ability to distinguish the two groups 
remained high with AUCs ranging from 0.85 to 0.97 for 
the individual markers and a sensitivity and specificity 
for the biomarker panel of 100% and 83%, respectively 
(Figure 2D). AUCs for the combined biomarkers can be 
found in Figure S2B– D, including all PSC, PSC- control 
> 36, and PSC- dysplasia as controls, respectively.
Of further interest, the bile samples from the CCA- 
PSC ≤ 12 patients, all positive for the methylation panel, 
were collected from patients with both early- stage and 
late- stage cancer at diagnosis (0– 2 and 3– 4), differ-
ent tumor growth patterns (mass- forming, periductal- 
infiltrating, and intraductal- growing), tumor size (< 3, 
3– 5, and > 5 cm), and anatomical location (intrahepatic 
CCA [iCCA], perihilar CCA [pCCA], and extrahepatic 
CCA [dCCA]) (Tables 2 and 3). Thus, the methylation 
panel achieved a sensitivity of 100% and a specificity of 
90% for detecting CCA in patients with underlying PSC, 
including dysplasia, up to 12 months prior to a confirmed 
CCA diagnosis and irrespective of clinical and molecular 
features (Table 3). All CCA samples negative for meth-
ylation were analyzed > 12 months prior to CCA diag-
nosis (Table S1). Of note, no correlation was observed 
between age and methylation among CCA- PSC for any 
of the four genes. For CNRIP1 and VIM a weak correla-
tion was observed among patients with PSC (Table S3).
DNA methylation in patients with PSC and 
underlying biliary dysplasia
To investigate if methylation levels of one or more 
markers in the four- gene panel increased stepwise 
in bile derived from benign, dysplastic, and malignant 
stages of disease, we compared the methylation levels 
of the four genes in the PSC- dysplasia group (n = 23) 
with the benign PSC- control > 36 group (n = 170) and 
the CCA- PSC ≤ 12 group (n = 28). The normalized 
methylation levels in the benign PSC and the PSC- 
dysplasia groups compared with the CCA group were 
significantly different for all four markers (Figure S3). 
Although no significant difference in methylation levels 
for any of the four markers was observed between the 
PSC- dysplasia group and the PSC- control > 36 group, 
an increase in methylation status was observed from 
the PSC- control > 36 group (7%) to the PSC- dysplasia 
group (17%) and to CCA (100%; Fisher's exact, 
p < 0.001) (Table S4).
Comparison of the methylation panel with CA 
19- 9 levels and brush cytology in indicating 
CCA in PSC
We also wanted to compare the results of the methyla-
tion panel in bile with the informativeness of CA 19- 9 
levels and conventional brush cytology assessments in 
detecting CCA in PSC. Because FISH analyses were 
not available for the majority of the samples, no com-
parisons were made between FISH and the methyla-
tion panel.
Of the 28 CCA- PSC ≤ 12 patients, CA 19- 9 levels 
were obtained from 25 patients, of whom 14 (56%) had 
a CA 19- 9 level > 100 U/ml. The biomarker panel was 
positive in all of these 14 patients (100% sensitivity). In 
addition, the biomarker panel was positive in all of the 
11 samples with a CA 19- 9 level < 100 U/ml (Table 4 
and Figure 3). Among the 203 patients with PSC with 
valid DNA biomarker results, CA 19- 9 measurements 
were available for 193 patients, including 13 (7%) with 
a CA 19- 9 level > 100 U/ml and 180 (93%) with a CA 
19- 9 level < 100 U/ml. The biomarker panel was neg-
ative in 92% of the patients with CA 19- 9 > 100 U/ml 
(n = 13) and in 90% of the patients with CA 19- 9 < 100 
U/ml (n = 180) (Table 4). Including only PSC- control > 
36, the biomarker panel was negative in 100% of the 
patients with CA 19- 9 > 100 U/ml. Thus, the high sensi-
tivity (100%) of the biomarker panel for CCA diagnosis 
was independent of CA 19- 9 level, and the specificity 
remained high (> 90%) in patients with CA 19- 9 level 
above and below 100 U/ml.
In the CCA- PSC ≤ 12 group parallel cytology spec-
imens from biliary brushings had been obtained for 
22 patients (24 samples). Among these, brush cytol-
ogy samples were not conclusive (acellular or nondi-
agnostic/scarce material) in seven samples (29%), of 
which all (100%) were positive for the methylation panel 
(Figure 3). Of the remaining 17 samples with conclu-
sive results, 12 (71%) were scored as positive for low- 
grade or high- grade dysplasia, while the combined 
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TA B L E  3  Associations between methylation of the biomarker panel and clinical and molecular features
CCA-­PSC­≤­12 CCA- PSC > 12
Total n Pos. n (%) Neg. n (%) Total n Pos. n (%) Neg. n (%)
No. of patients 28 28 (100) 0 (0) 10 2 (20) 8 (80)
Gender
Male 20 20 (100) 0 (0) 9 1 (11) 8 (89)
Female 8 8 (100) 0 (0) 1 1 (100) 0 (0)
AJCC (8th edition)
0– 2 7 7 (100) 0 (0) 1 0 (0) 1 (100)
3– 4 19 19 (100) 0 (0) 5 1 (20) 4 (80)
NA 2 2 (100) 0 (0) 4 1 (25) 3 (75)
Tumor location
iCCA 8 8 (100) 0 (0) 6 1 (17) 5 (83)
pCCA 13 13 (100) 0 (0) 2 0 (0) 2 (100)
dCCA 5 5 (100) 0 (0) 2 1 (50) 1 (50)
xCCA 2 2 (100) 0 (0) – – – 
Perineural growth
Yes 11 11 (100) 0 (0) 1 0 (0) 1 (100)
No 2 2 (100) 0 (0) – – – 
NA 15 15 (100) 0 (0) 9 2 (22) 7 (78)
Vascular encasement
Yes 5 5 (100) 0 (0) 1 0 (0) 1 (100)
No 9 9 (100) 0 (0) 1 0 (0) 1 (100)
NA 14 14 (100) 0 (0) 8 2 (25) 6 (75)
Differentiation
Low 3 3 (100) 0 (0) 1 0 (0) 1 (100)
Medium 10 10 (100) 0 (0) 1 0 (0) 1 (100)
High 1 1 (100) 0 (0) – – – 
NA 14 24 (100) 0 (0) 8 2 (25) 6 (75)
Growth pattern
Mass- forming 8 8 (100) 0 (0) 2 0 (0) 2 (100)
Periductal- infiltrating 5 5 (100) 0 (0) 1 1 (100) 0 (0)
Intraductal- growing 1 1 (100) 0 (0) – – – 
NA 14 14 (100) 0 (0) 7 1 (14) 6 (86)
Tumor diameter
<3 cm 7 7 (100) 0 (0) – – – 
3– 5 cm 8 8 (100) 0 (0) 1 0 (0) 1 (100)
>5 cm 6 6 (100) 0 (0) 4 1 (25) 3 (75)
NA 7 7 (100) 0 (0) 5 1 (20) 4 (80)
Resection margins
R0 8 8 (100) 0 (0) 1 0 (0) 1 (100)
R1 5 5 (100) 0 (0) 1 0 (0) 1 (100)
NA 15 15 (100) 0 (0) 8 2 (25) 6 (75)
Age at bile sampling, years
10– 29 1 1 (100) 0 (0) – – – 
30– 39 4 4 (100) 0 (0) 2 0 (0) 2 (100)
40– 49 6 6 (100) 0 (0) 2 1 (50) 1 (50)
(Continues)
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methylation panel was scored as positive in 100% of 
the samples (17/17) (Figure 3).
Among the PSC- control > 36 group (n = 170), par-
allel bile (methylation) and brush cytology results 
were available for 127 patients. Among these pa-
tients brush cytology was not conclusive (acellular 
or nondiagnostic material) in 42 patients (33%). Of 
the remaining 85 patients, all scored as negative for 
dysplasia; 80 (94%) were also negative for the meth-
ylation panel.
High concordance in methylation status 
between multiple samples from the 
same patient
For 52 patients, including four with CCA- PSC and 48 
with PSC, multiple samples (two to four) were ana-
lyzed. For the majority of the patients where longitu-
dinal sampling was present, disease category did not 
change during the sampling period (e.g., all samples 
from the same patient belonged to the CCA- PSC ≤ 
12 group or to the PSC- control > 36 group). For the 
four patients with CCA (eight samples), a 100% con-
cordance in methylation status for the biomarker panel 
was observed, while for the patients with PSC, 41 of 48 
(85%) had concordant methylation results (Figure S4). 
None of the PSC samples with deviating results (one 
sample scored as negative for the biomarker panel 
and one sample scored as positive for the biomarker 
panel) were collected during ongoing acute cholangitis. 
However, the majority of the samples with deviating re-
sults had been collected > 2 years apart.
In addition, prior to this effort we analyzed the bio-
markers in biliary brushes and tissue samples.[15,22] 
Figure S5 provides a direct comparison of methylation 
in bile, brush, and tissue of the four biomarkers in a 
subset of the samples (54 patients) included in previ-
ous efforts. In general, there was a high concordance 
in methylation status between the different materials for 
the same patients.
DNA methylation level and association 
with survival
To investigate if the level of methylation in bile could 
have an effect on survival, we did a log rank test. 
Dividing the CCA- PSC ≤ 12 samples into high (normal-
ized DNA methylation level > 10) and 0/low (normal-
ized DNA methylation level < 10) level of methylation 
showed that patients with a high level of methylation 
had a tendency for shorter overall survival compared 
to patients with no or a low level of methylation (CDO1, 
p = 0.059; CNRIP1, p = 0.016; SEPT9, p = 0.078; and 
VIM p = 0.203) (Figure S6).
CCA-­PSC­≤­12 CCA- PSC > 12
Total n Pos. n (%) Neg. n (%) Total n Pos. n (%) Neg. n (%)
50– 59 9 9 (100) 0 (0) 5 1 (20) 4 (80)
60– 79 8 8 (100) 0 (0) 1 0 (0) 1 (100)
IBD
UC 19 19 (100) 0 (0) 3 0 3 (100)
Crohn's disease 4 4 (100) 0 (0) 1 1 (100) 0 (0)
None 4 4 (100) 0 (0) 5 1 (20) 4 (80)
NA 1 1 (100) 0 (0) 1 0 (0) 1 (0)
CA 19- 9
>100 U/ml 14 14 (100) 0 (0) 0 – – 
<100 U/ml 11 11 (100) 0 (0) 10 2 (20) 8 (80)
NA 3 3 (100) 0 (0)
Bile origin
ERCP 26 26 (100) 0 (0) 10 2 (20) 8 (80)
Resection 1 1 (100) 0 (0) – – – 
Transplantation 1 1 (100) 0 (0) – – – 
Alive
Yes 9 9 (100) 0 (0) 1 1 (100) 0 (0)
No 19 19 (100) 0 (0) 9 1 (11) 8 (89)
Abbreviations: AJCC 0– 4, American Joint Committee on Cancer classification stages 0– 4; IBD, inflammatory bowel disease; NA, not available; Neg., negative 
for the biomarker panel (none of the four markers methylated); Pos., positive for the biomarker panel (one or more of the four markers methylated); UC, 
ulcerative colitis.
TA B L E  3  (Continued)
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CCA without underlying PSC versus other 
NM liver disease
The methylation panel has potential to detect 
CCA in a non- PSC setting
Finally, to investigate the potential of the biomarkers to 
also detect CCA in a non- PSC setting, we compared 
the CCA samples derived from patients without under-
lying PSC (n = 6) with samples from patients with other 
NM liver diseases (n = 24). Results for the individual bi-
omarkers are summarized in Figure S7, showing AUCs 
of 0.78 (CDO1), 1.00 (CNRIP), 0.75 (SEPT9), and 0.90 
(VIM). Combined, the biomarker panel had a sensitivity 
of 100% and a specificity of 100% for distinguishing the 
two groups. Although we had few samples, these data 
show that the biomarkers have the potential to also dif-
ferentiate CCA without underlying PSC from benign 
non- PSC liver diseases. For clinical and histopatho-
logical data on CCA and other NM liver diseases, see 
Table S5A,B.
DISCUSSION
By analyzing an exceptionally large series of bile sam-
ples from well- characterized patients, we demonstrate 
that four DNA methylation biomarkers accurately dif-
ferentiate patients with CCA from patients with NM 
liver disease. The diagnostic accuracy for CCA was 
high both in sporadic and in PSC- associated cancer, 
underscored by high specificity and the finding of posi-
tive methylation markers in all bile samples obtained 
up to 12 months prior to a confirmed CCA diagnosis. 
Furthermore, we have prior to this effort shown that the 
markers were highly methylated in CCA tumor tissue,[22] 
then in biliary brushes.[15] In the current study the utility 
of the methylation panel for early CCA diagnosis was 
validated using ddPCR in a limited amount of bile, em-
phasizing the robustness of the biomarkers. As such, 
this work represents a major advance in the field. The 
promising results suggest a potential for using these 
DNA methylation markers in bile (1) to complement cur-
rent detection methods for CCA and (2) for CCA sur-
veillance in patients with PSC. This also represents one 
of the largest liquid biopsy– derived biomarker studies 
in PSC- CCA to date.[14]
Two previous studies have also suggested DNA 
methylation analyses of bile as a possible modality 
to detect CCA. Klump et al.[23] reported that cyclin- 
dependent kinase inhibitor 2A (CDKN2A) was methyl-
ated in 52% (p16) and 48% (p14) of bile samples from 
patients with CCA and in only 6% of healthy individuals. 
Although promising, as a proof of concept for CCA de-
tection using bile, CDKN2A methylation was also pres-
ent in 46% of patients with PSC without an established 
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detection of CCA in patients with PSC.[23] Shin et al.[24] 
analyzed 17 aberrantly methylated biomarkers in dCCA 
in a training and a validation set of bile specimens (53 
CCA and 32 NM controls). The four best- performing 
panels from these two sets were then analyzed in an 
independent test set (24 CCA and 16 NM controls). With 
100% specificity and sensitivities of 70%, 74%, and 83% 
for the training, validation, and test sets, respectively, 
the best- performing marker panel showed potential for 
accurate dCCA detection.[24] However, no PSC controls 
were included in the study. Because inflammation, as 
observed in PSC, is known to affect the methylation pat-
tern,[25] the lack of PSC controls could affect the speci-
ficity of a potential detection test aimed at patients with 
PSC. In our study, the few false positives detected were 
all among the PSC controls; and if only including other 
NM liver diseases excluding PSC, we obtained a spec-
ificity of 100%. In general, we further observed higher 
methylation levels in patients with CCA and underlying 
PSC compared to those with CCA but without PSC (not 
shown). This has also been reported by others, using 
peptide markers in urine[26] and bile.[27]
Using blood to identify biomarkers is also attractive 
for cancer surveillance, considering both compliance 
and availability. Two genes, short stature homeobox 2 
and SEPT9, have been reported to be methylated in 
35% and 25%, respectively, of plasma samples from pa-
tients with CCA, with 99% specificity.[28] Although these 
findings are interesting and the specificity is good, the 
low sensitivity limits the usefulness of the markers as 
surveillance tools in a clinical setting. The performance 
in blood was furthermore poorer than that in tissue, 
leading one to question whether the amount of circu-
lating cell free tumor DNA in blood is high enough for 
early and robust detection of CCA.[28] Because bile is 
drained directly from the biliary tract where the primary 
tumor resides, it is reasonable to believe that bile con-
tains higher concentrations of tumor DNA from CCA 
compared to blood, and therefore may prove superior 
to blood for early and accurate CCA diagnosis.
So far, no evidence- based surveillance strategy ex-
ists for CCA in patients with PSC. Current practice in-
cludes interval screening with serum- based CA 19- 9 
and ultrasound or MR imaging/cholangiopancreatog-
raphy. If results are positive, ERCP with biliary brush 
cytology is typically performed,[8,29– 32] often in combi-
nation with FISH.[31] Other surveillance strategies also 
exist, including using ERCP and brush cytology as 
primary surveillance tools.[33,34] Both CA 19- 9[31] and 
imaging[32] display suboptimal accuracy for CCA detec-
tion, although MRI was recently reported to be superior 
to ultrasound for detection of early- stage CCA in as-
ymptomatic patients with PSC.[35] The specificity of bil-
iary brush for cytology and FISH is reported to be high 
(pooled specificity 97% and 96%, respectively), but 
the sensitivity is variable and often low (pooled sensi-
tivity 47% and 50%, respectively).[36,37] False- negative 
F I G U R E  3  Comparison of DNA methylation in bile with 
CA 19- 9 levels and biliary brush cytology. Red circle, sample 
scored as positive for methylation/cytology/CA 19- 9; white circle, 
sample scored as negative for methylation/cytology/CA 19- 9. The 
methylation panel was considered positive if one or more of the four 
biomarkers were methylated. Biliary brush cytology was scored 
positive if low/moderate- grade or high- grade dysplasia was identified 
and negative if only normal cells were identified. If more than one 
brush sample was taken, the case was scored based on the highest 
grade of dysplasia found. In cases where the sample was scored 
between two grades of dysplasia, the highest grade was used. For 
CA 19- 9 levels, 100 U/ml was used as the threshold: a CA 19- 9 level 
> 100 U/ml was considered positive, while a CA 19- 9 level < 100 U/
ml was considered negative. The “b” samples are not included in the 
biomarker analysis. NA, not available; NC, acellular or nondiagnostic/
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results may occur when the tumor resides in areas not 
accessible to or not targeted by brush cytology sam-
pling. It can further be challenging to obtain adequate 
cytological material for evaluation due to the fibrotic 
and desmoplastic process in PSC and CCA.[19] Our 
findings demonstrate the challenge of obtaining appro-
priate biliary brush material for diagnostic purposes, 
with a large proportion of the brush cytologies in the 
CCA group and in the benign PSC group not being 
informative (~30%). The performance of biliary brush 
cytology is also largely dependent on the individual 
endoscopists and cytopathologists. This may lead to 
considerable variability in the diagnostic informative-
ness of biliary brush cytology between centers.[38] In 
contrast, it is easier to standardize methodologies for 
bile sampling and methylation profiling. Also, using bile 
as diagnostic material for CCA, the chance of obtaining 
representative material increases because cells and 
DNA are shed into bile independently of tumor localiza-
tion. Indeed, using highly sensitive ddPCR methodol-
ogy in limited amounts of bile, we successfully detected 
alterations in methylation levels that robustly differenti-
ated patients with CCA from those without CCA, includ-
ing in patients with underlying PSC. The high sensitivity 
for CCA detection was irrespective of clinical and mo-
lecular features, including cancer stage at diagnosis, 
tumor growth pattern, tumor size, anatomical location, 
and CA 19- 9 levels. The few samples from patients with 
PSC with a later confirmed CCA diagnosis not detected 
by the biomarkers included bile samples collected 
> 12 months prior to a clinical diagnosis. Hence, there 
is a high chance that these patients had not developed 
CCA at the time of bile sampling.
The current study included CCA- PSC samples from 
three independent centers from three different coun-
tries. Unfortunately, due to the rarity of the disease, 
there were too few samples to include them as three 
independent series. We do, however, observe that the 
markers show 100% sensitivity among the CCA- PSC ≤ 
12 group, irrespective of center/country, with similar high 
specificities in the PSC- control > 36 group (Sweden, 
100%; Finland, 90%; Norway, 93%). Despite our prom-
ising findings, validation in larger multicenter sample 
series is warranted. Ideally, such analyses should be 
performed long- term, longitudinally, in a large prospec-
tive cohort of bile samples from patients with PSC, to 
see whether patients with PSC who later develop CCA 
show early signs of methylation, and further to system-
atically compare the accuracy of the methylation panel 
with conventional diagnostic measures for CCA. The 
current study demonstrates that methylation changes 
may be detected up to 12 months prior to standard 
CCA detection methods. Of further interest, patients 
with biliary dysplasia, who are at higher risk of develop-
ing CCA,[39] displayed a higher methylation frequency 
(17%) compared to patients with PSC without findings 
of dysplasia (7%). Still, including longitudinal data and 
consecutive bile samples from patients with PSC could 
give a better indication of how long prior to malignancy 
these methylation changes are expected to occur. It 
might also give an indication of whether these changes 
are associated with biliary dysplasia or predominantly 
represent markers for CCA development that are inde-
pendent of the dysplasia– carcinoma sequence. Four 
of 12 (33%) PSC samples from patients without an es-
tablished CCA diagnosis but with < 36 months of fol-
low- up were methylated for the biomarkers. We cannot 
rule out that some of these might be false positives, 
caused by severe inflammation, cholestasis, or other 
benign factors in the bile ducts. Another possibility is 
that these patients represent a high- risk group for CCA 
development. The PSC samples included in the study 
are derived from tertiary center referrals of patients un-
dergoing ERCP, surgical resection, or liver transplanta-
tion. As such, the PSC samples included are enriched 
for advanced PSC cases, and it is not unlikely that a 
subgroup of these patients is at higher risk for CCA 
development. However, we observed no association 
between concurrent bacterial acute cholangitis or cir-
rhosis and DNA methylation level of any of the individ-
ual markers or with the methylation panel.
Interestingly, the individual DNA methylation mark-
ers analyzed in the current study for their diagnostic 
potential have also been evaluated by others for their 
prognostic value. Nakamoto et al. reported that the 
overall survival in patients with dCCA was poorer in 
patients with hypermethylated CDO1,[40] while a study 
by Chen et al. showed that low expression of CNRIP1, 
caused by DNA methylation, was associated with poor 
prognosis in patients with iCCA.[41] DNA methylation 
level of SEPT9 in tissue showed, on the other hand, 
no correlation with overall survival.[28] Although an in- 
depth analysis of the prognostic value of the four bio-
markers was outside the scope of the current study, we 
did a log rank test to investigate if the methylation level 
in bile could have an effect on survival, observing that 
our results were in agreement with what was reported 
by others.
In conclusion, by analyzing an unprecedented large 
series of bile samples predominantly derived from pa-
tients with PSC, we have shown that testing for DNA 
methylation biomarkers in bile detects CCAs in patients 
with PSC with high accuracy and at an earlier stage 
than conventional modalities. The findings suggest 
that these biomarkers have potential to complement 
standard modalities for improved CCA detection and 
potentially for CCA surveillance in patients with PSC. 
Prospective validation of the markers in a clinical set-
ting is warranted.
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